Related Experiment Video
Updated: Sep 3, 2025
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
15.0K
Integrin Signaling Shaping BTK-Inhibitor Resistance
Laura Polcik1,2, Svenja Dannewitz Prosseda1, Federico Pozzo3
1Department of Internal Medicine I, Faculty of Medicine and Medical Center, University of Freiburg, 79106 Freiburg, Germany.
Cells
|July 27, 2022
Summary
Very late antigen-4 (VLA-4) integrin activation may drive cancer drug resistance independently of Bruton's tyrosine kinase (BTK) signaling in chronic lymphocytic leukemia (CLL). This highlights VLA-4 as a potential therapeutic target for overcoming BTK inhibitor resistance.
Area of Science:
- Oncology
- Cell Biology
- Immunology
Background:
- Integrins, like beta1 integrins, are crucial for tumor cell adhesion and metastasis.
- Very late antigen-4 (VLA-4), a beta1 integrin, is implicated in therapy resistance in various cancers, including chronic lymphocytic leukemia (CLL).
- Cell adhesion-mediated drug resistance is a significant challenge in cancer treatment.
Purpose of the Study:
- To explore the role of VLA-4 inside-out signaling in cancer therapy resistance.
- To discuss the implications of VLA-4 activation in the context of Bruton's tyrosine kinase (BTK) inhibitors for CLL treatment.
- To elucidate the mechanisms of cell adhesion-mediated drug resistance.
Main Methods:
- Review of current literature on integrin signaling, VLA-4 function, and BTK inhibitors in CLL.
- Analysis of VLA-4 activation pathways and their relationship with BTK signaling.
- Discussion of therapeutic strategies targeting VLA-4 and cell adhesion-mediated drug resistance.
Main Results:
- VLA-4 activation is a complex process involving inside-out signaling pathways.
- VLA-4 can be activated independently of BTK signaling, potentially contributing to resistance against BTK inhibitors.
- Cell adhesion mediated by VLA-4 may protect leukemic cells from therapy.
Conclusions:
- VLA-4 represents a potential therapeutic target for overcoming resistance to BTK inhibitors in CLL.
- Understanding VLA-4 signaling is critical for developing alternative or combination therapies for resistant CLL.
- Targeting cell adhesion mechanisms could enhance the efficacy of cancer treatments.
Related Concept Videos
01:17Intracellular Signaling Affects Focal Adhesions
2.8K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.8K
01:15Activation of Integrins
3.6K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
3.6K
01:20The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
01:22PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
01:16TGF - β Signaling Pathway
7.6K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K
01:10Integrins
4.1K
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
4.1K